OKUR

OnKure Therapeutics, Inc. NASDAQ Listed Apr 8, 2021

Healthcare ·Biotechnology ·US · onkuretherapeutics.com

$3.85

-1.03% vs $3.89

Mkt Cap $52.0M

52w Low $2.32 51.9% of range 52w High $5.27

50d MA $4.19 200d MA $3.64

P/E (TTM) -1.1x

EV/EBITDA —

P/B 0.9x

Debt/Equity 0.0x

ROE -105.9%

P/FCF -1.0x

RSI (14) 34.70

ATR (14) $0.29

Beta 0.15

50d MA $4.19

200d MA $3.64

Avg Volume 134.8K

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

SIC Code

2834

CIK (SEC)

1637715

Phone

720 307 2892

6707 Winchester Circle · Boulder, CO 80301 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Aug 4, 2026	AMC	-0.54	-0.31	+42.1%	4.10	+0.7%	+1.5%	-0.2%	-0.2%	-1.9%	+0.7%	—
May 5, 2026	AMC	-0.81	-1.11	-37.0%	4.52	-4.0%	-10.0%	-2.7%	-1.3%	-12.0%	-1.5%	—
Mar 12, 2026	AMC	-1.15	-0.99	+13.9%	3.52	+6.2%	+7.4%	+3.2%	+3.1%	-0.2%	+9.2%	—
Nov 6, 2025	AMC	-1.20	-1.09	+9.2%	3.16	-2.5%	-7.0%	+4.4%	+3.3%	-2.8%	+1.9%	—
Aug 12, 2025	AMC	-1.23	-1.14	+7.3%	2.00	+9.5%	+20.0%	+11.2%	-5.2%	+10.7%	-2.1%	—
May 6, 2025	AMC	-1.32	-1.19	+9.8%	2.23	+0.9%	-3.6%	-7.0%	-4.0%	+1.6%	-5.6%	—
Mar 10, 2025	AMC	-0.86	-1.37	-59.3%	4.96	+5.8%	-0.2%	-3.2%	-3.5%	-0.2%	+4.6%	—
Nov 7, 2024	AMC	-0.97	-1.10	-13.4%	17.19	-1.1%	+2.3%	-0.2%	-1.5%	-2.4%	+0.1%	—
Aug 13, 2024	AMC	-1.00	-1.60	-60.0%	13.80	-4.3%	+6.5%	+6.1%	-0.6%	+1.9%	+0.0%	—
May 7, 2024	AMC	-0.37	-0.25	+32.4%	17.40	+0.6%	+5.2%	+1.6%	-2.7%	-12.2%	+1.9%	—
Mar 28, 2024	AMC	-5.78	-7.00	-21.1%	16.60	-0.6%	+2.4%	+0.6%	+0.0%	+1.2%	-1.2%	—
Dec 31, 2023	AMC	-5.78	-7.00	-21.1%	—	—	—	—	—	—	—	—
Nov 13, 2023	AMC	-5.71	-5.70	+0.3%	62.50	-0.6%	+1.4%	+4.3%	-7.7%	+10.8%	-7.4%	—
Sep 30, 2023	AMC	-5.71	-1.44	+74.8%	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	-5.30	-0.61	+88.4%	65.60	+12.0%	-2.3%	+5.9%	+0.0%	-0.6%	+8.4%	—
Mar 31, 2023	AMC	-6.04	-0.65	+89.2%	59.80	+0.3%	-6.0%	-3.2%	+3.9%	-0.9%	+7.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.78	$3.86	+2.1%	+3.2%	+3.1%	-0.2%	+9.2%	-4.3%
Aug 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.82	$2.76	-2.1%	-2.5%	+1.8%	+0.4%	-2.1%	+0.7%
Mar 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.82	$4.91	+1.9%	+1.9%	+1.8%	+0.0%	+1.0%	-1.8%
Mar 11	Oppenheimer	Maintains	Outperform → Outperform	—	$4.96	$5.25	+5.8%	-0.2%	-3.2%	-3.5%	-0.2%	+4.6%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.19	$17.00	-1.1%	+2.3%	-0.2%	-1.5%	-2.4%	+0.1%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
Jun 22, 2026	Saccomano Nicholas A	President and CEO	Sell	86	$4.40	$378	11,247	-2.77%	-2.19%
Jun 22, 2026	Leverone Jason A.	Chief Financial Officer	Sell	303	$4.40	$1K	18,802	-2.77%	-2.19%

Institutional (13F) — Top 0 All ↗

No 13F holders found.

Mutual Funds / ETFs (N-PORT) — Top 3 All ↗

#	Fund	Shares	Value	Period
1	Ultra-Small Company Fund	16,293	$67K	Mar 2026
2	Avantis Total Equity Markets ETF	504	$1K	Feb 2026
3	Russell 2000(R) 1.5x Strategy Fund	7	$32	Jun 2026

Data updated apr 26, 2026 5:13pm · Source: financialmodelingprep.com